Unity of bowel-lung axis and the role of beneficial microbiota in anti-infectious protection
DOI: 10.32364/2618-8430-2021-4-4-355-361
T.E. Taranushenko
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk,
Russian Federation
NIH Human Microbiome Project determined particular attention of the worldwide medical community to the study of the human microbiome and the assessment of the impact of symbiont microorganisms in the development of various (not only gastrointestinal) disorders. Potential interactions between the bowel and lungs (bowel-lung axis) via microbiota that allow for the possible involvement of microorganisms in the development of respiratory diseases are actively debated. This paper reviews studies on the pattern of interactions between bowel and lungs in infectious diseases associated with mucosal inflammation. The association between gut microbiota and the protective barrier of the respiratory tract based on known mechanisms and novel data derived from recent studies on SARS-CoV-2 is discussed. The relevance of beneficial bacteria (symbionts) in local and systemic immune responses, their disease-modifying and, eventually, therapeutic strategy-modifying properties, the ability to be a resource of preventive medicine and an orchestrating tool for infections are addressed. Practitioners’ difficulties with probiotics in preventive and treatment schedules for various conditions are highlighted. Finally, the use of probiotics in children with respiratory infections and COVID-19 is uncovered.
Keywords: microbiota, microbiome, probiotics, children, mucosal immunity, Bifidobacterium.
For citation: Taranushenko T.E. Unity of bowel-lung axis and the role of beneficial microbiota in anti-infectious protection. Russian Journal of Woman and Child Health. 2021;4(4):355–361 (in Russ.). DOI: 10.32364/2618-8430-2021-4-4-355-361.
Acknowledgment
The authors and Editorial Board are grateful to "PROGRESS" JSC for providing full-text foreign articles required to write the review.
About the author:
Tatyana E. Taranushenko — Dr. Sc. (Med.), Professor, Honorary Doctor of the Russian Federation, Head of the Department of Pediatrics of the Institute of Postgraduate Education, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; 1, Partizan Zheleznyak str., Krasnoyarsk, 660022, Russian Federation; ORCID iD 0000-0003-2500-8001.
Contact information: Tatyana E. Taranushenko, e-mail: tetar@rambler.ru.
Financial Disclosure: the author has no a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 23.09.2021.
Revised 18.10.2021.
Accepted 12.11.2021.
2. Ahlawat S., Asha, Sharma K.K. Gut–organ axis: a microbial outreach and networking. Lett Appl Microbiol. 2021;72(6):636–668. DOI: 10.1111/lam.13333.
3. De Oliveira G.L.V., Oliveira C.N.S., Pinzan S.F. et al. Microbiota modulation of the gut-lung axis in COVID-19. Front Immunol. 2021;12:635471. DOI: 10.3389/fimmu.2021.635471.
4. Copeland C.S. The World Within Us: Health and the Human Microbiome. Healthcare J New Orleans. 2017;6(5)21–26.
5. Kenya H., Littman D.R. The microbiota in adaptive immune homeostasis and disease. Nature. 2016;535(7610):75–84. DOI: 10.1038/nature18848.
6. Van Amersfoort E.S., Van Berkel T.J.C., Kuiper J. Receptors, Mediators, and Mechanisms Involved in Bacterial Sepsis and Septic Shock. Clin Microbiol Rev. 2003;16(3):379–414. DOI: 10.1128/CMR.16.3.379-414.2003.
7. Ahmadi Badi S., Tarashi S., Fateh A. et al. From the Role of Microbiota in Gut-Lung Axis to SARS-CoV-2 Pathogenesis Mediators Inflamm. 2021:6611222. DOI: 10.1155/2021/6611222.
8. Lee Y.S., Kim T.Y., Kim Y. et al. Microbiota-derived lactate promotes hematopoiesis and erythropoiesis by inducing stem cell factor production from leptin receptor+niche cells. Exp Mol Med. 2021;53:1319–1331. DOI: 10.1038/s12276-021-00667-y.
9. Spagnolello O., Pinacchio C., Santinelli L., Vassalini P. Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection. Chemotherapy. 2021;66(1–2):24–32. DOI: 10.1159/000515344.
10. Din A.U., Mazhar M., Waseem M. et al. SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role. J Biomed Pharmacother. 2021;133:110947. DOI: 10.1016/j.biopha.2020.110947.
11. Zhou D., Wang Q., Liu H. Coronavirus disease 2019 and the gut–lung axis. Int J Infect Dis. 2021;113:300–307. DOI: 10.1016/j.ijid.2021.09.013.
12. Houghteling P.D., Walker W.A. Why is initial bacterial colonization of the intestine important to the infant’s and child’s health? J Pediatr Gastroenterol Nutr. 2015;60(3):294–307. DOI: 10.1097/MPG.0000000000000597.
13. Budden K.F., Gellatly S.L., Wood D.L.A. et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol. 2017;15(1):55–63. DOI: 10.1038/nrmicro.2016.142.
14. Henry B.M., Santos de Oliveira M.H., Benoit S. et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–1028. DOI: 10.1515/cclm-2020-0369.
15. Bain C.C., Cerovic V. Interactions of the microbiota with the mucosal immune system. Immunology. 2020;159:1–3. DOI: 10.1111/imm.13159.
16. Ahern P.P., Maloy K.J. Understanding immune-microbiota interactions in the intestine. Immunology. 2020;159(1):4–14. DOI: 10.1111/imm.13150.
17. Lin S., Mukherjee S., Lin J.L. et al. Mucosal immunity–mediated modulation of the gut microbiome by oral delivery of probiotics into Peyer’s patches. Sci Adv. 2021;7(20):eabf0677. DOI: 10.1126/sciadv.abf0677.
18. He L.H., Ren L.F., Li J.F. et al. Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection. Front Microbiol. 2020;11:1388. DOI: 10.3389/fmicb.2020.01388.
19. Hao Q., Dong B.R. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015;(2):CD006895. DOI: 10.1002/14651858.CD006895.pub3.
20. Li K.L., Wang B.Z., Li Z.P. et al. Alterations of intestinal flora and the effects of probiotics in children with recurrent respiratory tract infection. World J Pediatr. 2019;15(3):255–261. DOI: 10.1007/s12519-019-00248-0.
21. Depoorter L., Vandenplas Y. Probiotics in pediatrics. A review and practical guide. Nutrients. 2021;13:2176. DOI: 10.3390/nu13072176.
22. Grayson M.H., Camarda L.E., Hussain S.-R.A. et al. Intestinal Microbiota Disruption Reduces Regulatory T Cells and Increases Respiratory Viral Infection Mortality Through Increased IFNγ Production. Front Immunol. 2018;9:1587. DOI: 10.3389/fimmu.2018.01587.
23. Lee N.K., Paik H.D. Prophylactic effects of probiotics on respiratory viruses including COVID-19: a review. Food Sci Biotechnol. 2021;30(6):1–9. DOI: 10.1007/s10068-021-00913-z.
24. Paknahad Z., Moravejolahkami A.R. Probiotics Against Viruses; COVID-19 is a Paper Tiger: A Systematic Review. Endocr Metab Immune Disord Drug Targets. 2021;21(7):1252–1260. DOI: 10.2174/1871530320666200917114033.
25. Darbandi A., Asadi A., Ghanavati R. et al. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010–20. Int J Infect Dis. 2021;105:91–104. DOI: 10.1016/j.ijid.2021.02.011.
26. Hay A.D., Heron J., Ness A., ALSPAC study team. The prevalence of symptoms and consultations in pre-school children in the Avon Longitudinal Study of Parents and Children (ALSPAC): a prospective cohort study. Fam Pract. 2005;22:367–374. DOI: 10.1093/fampra/cmi035.
27. Fendrick A.M., Monto A.S., Nightengale B., Sarnes M. The economic burden of noninfluenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163(4):487–494. DOI: 10.1001/archinte.163.4.487.
28. Росстат. Здравоохранение в России 2018: статистический сборник. М.; 2018. [Rosstat. Healthcare in Russia 2018: statistical collection. M.; 2018 (in Russ.)].
29. Yizhong Wang, Xiaolu Li, Ting Ge et al. Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials. Medicine. 2016;95(31):e4509. DOI: 10.1097/MD.0000000000004509.
30. Georgia Véras de Araujo, Mário Henriques de Oliveira Junior, Décio Medeiros Peixoto, Emanuel Sávio Cavalcanti Sarinho. Probiotics for the treatment of upper and lower respiratory‐tract infections in children: systematic review based on randomized clinical trials. J Pediatr (Rio J). 2015;91(5):413–427. DOI: 10.1016/j.jped.2015.03.002.
31. Land W.G. The Role of Damage-Associated Molecular Patterns in Human Diseases. Sultan Qaboos Univ Med J. 2015;15(1):e9–e21. PMID: 25685392.
32. Li D., Wu M. Pattern recognition receptors in health and diseases. Sig Transduct Target The. 2021;6:291. DOI: 10.1038/s41392-021-00687-0.
33. Batra P., Dev Soni K., Mathur P. Efficacy of probiotics in the prevention of VAP in critically ill ICU patients: an updated systematic review and meta-analysis of randomized control trials. JAMA. 2021;326(11):1024–1033. DOI: 10.1001/jama.2021.13355.
34. Boson B., Legros V., Zhou B. et al. The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles (Research Article). J Biol Chem. 2021;296:100111. DOI: 10.1074/jbc.RA120.016175.
35. Stavropoulou E., Bezirtzoglou E. Probiotics as a Weapon in the Fight Against COVID-19. Front Nutr. 2020;7:614986. DOI: 10.3389/fnut.2020.614986.
36. Захарова И.Н., Бережная И.В., Кучина А.Е., Дедикова О.В. Пробиотик Lactobacillus reuteri DSM 17938: что известно о нем сегодня? Медицинский cовет. 2019;(17):236–242. DOI: 10.21518/2079-701X-2019-17-236-242. [Zakharova I.N., Berezhnaya I.V., Kuchina A.Е., Dedikova O.V. Probiotic Lactobacillus reuteri DSM 17938: what is known about it today? Medical Council. 2019;(17):236–242 (in Russ.)] DOI: 10.21518/2079-701X-2019-17-236-242.
37. Valeur N., Engel P., Carbajal N. et al. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol. 2004;70(2):1176–1181. DOI: 10.1128/AEM.70.2.1176-1181.2004.
38. Adinatha Y., Ida Bagus Subanada I.B., Arimbawa I.M. et al. The effectiveness of probiotic as adjuvant therapy of severe pneumonia in children below 5 years-old at Sanglah General Hospital, Bali, Indonesia. Bali Med J. 2020;9(1):390–394. DOI: 10.15562/bmj.v9i1.1773.
39. Picard C., Fioramonti J., Francois A. et al. Review article: bifidobacteria as probiotic agents — physiological effects and clinical benefits. Aliment Pharmacol Ther. 2005;22(6):495–512. DOI: 10.1111/j.1365-2036.2005.02615.x.
40. Marras L., Caputo M., Bisicchia S. et al. The Role of Bifidobacteria in Predictive and Preventive Medicine: A Focus on Eczema and Hypercholesterolemia. Microorganisms. 2021;9(4):836. DOI: 10.3390/microorganisms9040836.
41. Taipale T.J., Pienihäkkinen K., Isolauri E. et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in early childhood. Pediatr Res. 2016;79(1–1):65–69. DOI: 10.1038/pr.2015.174.
42. WGO Practice Guideline Probiotics and Prebiotics. (Electronic resource.) URL: www.worldgastroenterology.org. (access date: 08.21.2021)].
43. Taipale T., Pienihäkkinen K., Isolauri E. et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr. 2011;105(3):409–416. DOI: 10.1017/S0007114510003685.
44. Rizzardini G., Eskesen D., Calder P.C. et al. Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2012;107(6):876–884. DOI: 10.1017/S000711451100420X.
45. Jungersen M., Wind A., Johansen E. et al. The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12(®). Microorganisms. 2014;2(2):92–110. DOI: 10.3390/microorganisms2020092.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать